Synmosa Biopharma (Taiwan) Analysis
| 4114 Stock | TWD 33.50 0.10 0.30% |
Synmosa Biopharma is fairly valued with Real Value of 34.5 and Hype Value of 33.5. The main objective of Synmosa Biopharma stock analysis is to determine its intrinsic value, which is an estimate of what Synmosa Biopharma is worth, separate from its market price. There are two main types of Synmosa Biopharma's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Synmosa Biopharma's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Synmosa Biopharma's stock to identify patterns and trends that may indicate its future price movements.
The Synmosa Biopharma stock is traded in Taiwan on Taiwan OTC Exchange, with the market opening at 09:00:00 and closing at 13:30:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Taiwan. Synmosa Biopharma is usually not traded on No Trading . Market opens only for Clearing & Settlement 2, Adjusted Holiday / Chinese New Year 's Eve, Chinese New Year 's Eve, Chinese New Year, Dragon Boat Festival, National Day of the Republic of China, Chinese New Year 2, Chinese New Year 3, Adjusted Holiday 1, Adjusted Holiday 2, Mid - autumn / Moon Festival. Synmosa Stock trading window is adjusted to Asia/Taipei timezone.
Synmosa |
Synmosa Stock Analysis Notes
About 25.0% of the company shares are owned by insiders or employees . The book value of Synmosa Biopharma was presently reported as 15.83. The company last dividend was issued on the 11th of July 2022. Synmosa Biopharma had 1000000:1101600 split on the 9th of August 2024. Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. The company was incorporated in 1980 and is based in Taipei, Taiwan. SYNMOSA BIOPHARMA operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange. For more info on Synmosa Biopharma please contact the company at 886 2 8797 7100 or go to https://www.synmosa.com.tw.Synmosa Biopharma Investment Alerts
| Synmosa Biopharma generated a negative expected return over the last 90 days | |
| About 25.0% of the company shares are owned by insiders or employees |
Synmosa Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 15.75 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Synmosa Biopharma's market, we take the total number of its shares issued and multiply it by Synmosa Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Synmosa Profitablity
Synmosa Biopharma's profitability indicators refer to fundamental financial ratios that showcase Synmosa Biopharma's ability to generate income relative to its revenue or operating costs. If, let's say, Synmosa Biopharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Synmosa Biopharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Synmosa Biopharma's profitability requires more research than a typical breakdown of Synmosa Biopharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.18 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.09 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.09. Technical Drivers
As of the 13th of December 2024, Synmosa Biopharma has the Risk Adjusted Performance of (0.19), variance of 0.5264, and Coefficient Of Variation of (389.70). Synmosa Biopharma technical analysis provides you with a way to harness past market data to determine a pattern that measures the direction of the company's future prices. Please validate Synmosa Biopharma standard deviation, information ratio, maximum drawdown, as well as the relationship between the variance and treynor ratio to decide if Synmosa Biopharma is priced more or less accurately, providing market reflects its prevalent price of 33.5 per share.Synmosa Biopharma Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Synmosa Biopharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Synmosa Biopharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Synmosa Biopharma Outstanding Bonds
Synmosa Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Synmosa Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Synmosa bonds can be classified according to their maturity, which is the date when Synmosa Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Synmosa Biopharma Predictive Daily Indicators
Synmosa Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Synmosa Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 5288.21 | |||
| Daily Balance Of Power | (0.40) | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 33.63 | |||
| Day Typical Price | 33.58 | |||
| Price Action Indicator | (0.18) | |||
| Period Momentum Indicator | (0.10) |
Synmosa Biopharma Forecast Models
Synmosa Biopharma's time-series forecasting models are one of many Synmosa Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Synmosa Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Synmosa Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Synmosa Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Synmosa shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Synmosa Biopharma. By using and applying Synmosa Stock analysis, traders can create a robust methodology for identifying Synmosa entry and exit points for their positions.
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. The company was incorporated in 1980 and is based in Taipei, Taiwan. SYNMOSA BIOPHARMA operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Synmosa Biopharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Stock Screener Now
Stock ScreenerFind equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
| All Next | Launch Module |
Additional Tools for Synmosa Stock Analysis
When running Synmosa Biopharma's price analysis, check to measure Synmosa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synmosa Biopharma is operating at the current time. Most of Synmosa Biopharma's value examination focuses on studying past and present price action to predict the probability of Synmosa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synmosa Biopharma's price. Additionally, you may evaluate how the addition of Synmosa Biopharma to your portfolios can decrease your overall portfolio volatility.